丁苯酞在脑小血管病患者中的疗效观察及对Aβ、T淋巴细胞百分比的影响研究

Curative efficacy of Butylphthalide in treatment of Cerebral small vessels and its effectson A beta,T lymphocyte percentages

目的:探讨丁苯酞在脑小血管病患者中的疗效观察及对β-淀粉样蛋白(amyloidβ-protein,Aβ)、T淋巴细胞(T lymphocyte,T细胞)百分比的影响,为患者的临床治疗提供指导。方法:选取2017年4月到2019年4月我院收治的84例脑小血管病患者作为研究对象,以按照随机数表法分为观察组和对照组,各42例。对照组给予尼莫地平片治疗,观察组给予丁苯酞治疗。比较两组疗效、蒙特利尔认知量表(MOCA)、简易智能状态检查表(MMSE)、β-淀粉样蛋白(Aβ)、分化簇3(CD3)、辅助Th细胞(CD4)、白细胞分化抗原(CD8)水平变化情况和不良反应发生情况。结果:治疗后,观察组总有效率为92.86%,显著高于对照组的73.81%,差异有统计学意义;治疗前,两组MOCA、MMSE评分比较,差异无统计学意义;治疗后,两组MOCA、MMSE评分均明显提升,且观察组MOCA、MMSE评分(24.13±2.03分、29.83±1.88分)明显高于对照组(22.36±1.86分、27.58±1.53分),差异有统计学意义;治疗前,两组Aβ水平比较,差异无统计学意义;治疗后,两组Aβ水平均明显下降,且观察组Aβ水平(66.75±7.36ng/L)明显低于对照组(76.28±9.16 ng/L),差异有统计学意义;治疗前,两组T淋巴细胞水平比较,差异无统计学意义;治疗后,两组T淋巴细胞水平均明显下降,且观察组CD3^(+)、CD4^(+)(62.35±4.28%、43.28±3.92%)明显高于对照组(56.73±3.75%、37.85±3.14%),CD8^(+)(24.69±2.12%)低于对照组(29.36±2.47%),差异有统计学意义;两组不良反应总发生率分别为4.76%、21.43%,差异有统计学意义。结论:丁苯酞在脑小血管病患者中的疗效显著,可有效改善患者血清Aβ和T淋巴细胞水平,且不良反应少,值得临床推广应用。

Objective To study curative efficacy of butylphthalide in treatment of cerebral small vessels and its effectson A beta,t lymphocyte percentages Methods Eighty-four patients with cerebrovascular disease admitted to our hospital from April 2017 to April 2019 were selected as the research objects.They were divided into observation group and control group according to random number table method,42 cases in each group.The control group was treated with nimodipine tablets and the observation group was treated with butylphthalide soft capsules.The curative effect,Montreal Cognitive Scale(MOCA),Simple Mental State Examination(MMSE),beta-amyloid protein(Abet),differentiation cluster 3(CD3),helper Th cells(CD4),leucocyte differentiation antigen(CD8)levels and adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the observation group was 92.86%,which was significantly higher than that of the control group 73.81%.Before treatment,MOCA and MMSE scores of the two groups showed no statistically significant difference.After treatment,MOCA and MMSE scores of the two groups were significantly improved,and MOCA and MMSE scores of the observation group(24.13±2.03points,29.83±1.88points)were significantly higher than those of the control group(22.36±1.86points,27.58±1.53points),with statistically significant differences.Before treatment,there was no statistically significant difference in A beta level between the two groups.After treatment,the level of A beta in both groups was significantly decreased,and the level of A beta in the observation group(66.75±7.36ng/L)was significantly lower than that in the control group(76.28±9.16ng/L),with statistically significant difference.Before treatment,there was no statistically significant difference in T lymphocyte levels between the two groups.After treatment,T lymphocyte levels in both groups were significantly decreased,and CD3^(+)and CD4^(+)(62.35±4.28%,43.28±3.92%)in the observation group were significantly higher than those in the control group(56.73±3.75%,37.85±3.14%),and CD8^(+)(24.69±2.12%)were lower than those in the control group(29.36±2.47%),with statistically significant differences.The total incidence of adverse reactions in the two groups was 4.76%and 21.43%,respectively,with no statistically significant difference.Conclusion Butylphthalide has A significant effect in patients with small cerebral vascular disease,and can effectively improve the level of serum A beta and T lymphocytes in patients,with few adverse reactions,which is worthy of clinical application.